Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Featured trial
ADORED-Allergic Disease Onset Prevention Study  

STMC-103H is an oral capsule containing powder which will be mixed with a small amount of breastmilk, the participant’s formula, or a milk product. Siolta Therapeutics is testing this investigational drug for the prevention of allergic diseases, including atopic dermatitis (eczema), food allergy, asthma, and allergic rhinitis (hay fever).

  • 0 views
  • 13 Jan, 2025
  • 9 locations
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

The study will assess change in disease signs and symptoms. Upadacitinib is an investigational drug being developed for the treatment of HS. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given study drug and who will receive placebo …

  • 0 views
  • 19 Feb, 2024
A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin")

The purpose of this research study is to find out more about an investigational drug, 10XB-101, for people with fat under their chin which they would like to remove. The Sponsor of this study thinks there may be a chance this drug could be used to dissolve, or "melt" this …

  • 0 views
  • 19 Feb, 2024
First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors

The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone or in combination with programmed cell death protein-1 (PD-1) inhibitors in treating solid cancers. ABBV-CLS-579 is an investigational drug being developed for the treatment of solid tumors. The study has two arms - …

  • 0 views
  • 19 Feb, 2024
NasoShield in Healthy Adults to Study Safety and Immunogenicity

The purpose of this study is to evaluate the safety for up to two doses of NasoShield, to determine if antibodies that protect against anthrax are formed after treatment with NasoShield, and to determine whether the formation of these antibodies are affected by different positions of administration.

intrauterine device (iud)
tubal ligation
oophorectomy
hysterectomy
vasectomy
  • 0 views
  • 19 Feb, 2024
Trial For Report 001  

Test Comment here

  • 0 views
  • 19 Feb, 2024
  • 1 location
Cisplatin+Pembrolizumab+RT in Vulvar Cancer

This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: Cisplatin (standard of care drug) Pembrolizumab (investigational drug) Radiation Therapy (standard of care intervention)

excisional biopsy
liver metastasis
pediatric
squamous cell carcinoma of the vulva
vulvar carcinoma
  • 0 views
  • 19 Feb, 2024
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2

Embedded within the Master Study are individual drug substudies. Investigational Drug Sub-study A: Brigatinib

neurofibromatosis
multiple meningiomas
schwannoma
experimental drug
neurofibroma
  • 0 views
  • 19 Feb, 2024
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

castration-resistant prostate cancer
metastasis
bone lesion
bone scan
diphosphonates
  • 0 views
  • 19 Feb, 2024
A Study to Explore Personalized Treatment for Patients with Recurrent Gynecological Malignancies Based on MTB (RWS-MTB)

Attending physicians will determine the final treatment plan, integrating multidisciplinary recommendations with patient preferences, comorbidity considerations, drug toxicity assessments, insurance coverage for off-label medications, and the availability of investigational drug trials. This arm aims to observe and evaluate the clinical efficacy of personalized treatment plans developed through molecular tumor profiling …

  • 0 views
  • 17 Jan, 2025